Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
|
|
Heart Test Laboratories, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/13/2022 |
8-K
| Quarterly results|
Docs:
|
"HeartSciences Provides Business Update and Reports First Quarter Fiscal 2023 Financial Results Nearing Completion of Patient Recruitment in FDA Pivotal Clinical Validation Study of MyoVista® Remains on Track for MyoVista® FDA De Novo Resubmission in Current Fiscal Year Southlake, Texas, September 13, 2022 – Heart Test Laboratories, Inc. d/b/a HeartSciences , a medical technology company focused on applying innovative AI-based technology to an ECG to significantly expand and improve an ECG’s clinical usefulness by detecting cardiac dysfunction, today provided a business update and reported financial results for the fiscal first quarter ended July 31, 2022. Andrew Simpson, Chief Executive Officer of HeartSciences, commented, “We are nearing completion of patient recruitment for the FD..." |
|
|
|